S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
Log in
NASDAQ:OBCI

Ocean Bio-Chem Competitors

$11.33
+0.88 (+8.42 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.71
Now: $11.33
$11.54
50-Day Range
$9.88
MA: $11.97
$12.92
52-Week Range
$3.10
Now: $11.33
$22.55
Volume50,759 shs
Average Volume50,935 shs
Market Capitalization$107.20 million
P/E Ratio11.44
Dividend Yield0.77%
Beta0.39

Competitors

Ocean Bio-Chem (NASDAQ:OBCI) Vs. CDZI, HFFG, NOVS, CLXT, NBEV, and LNDC

Should you be buying OBCI stock or one of its competitors? Companies in the sector of "consumer staples" are considered alternatives and competitors to Ocean Bio-Chem, including Cadiz (CDZI), HF Foods Group (HFFG), Novus Capital (NOVS), Calyxt (CLXT), NewAge (NBEV), and Landec (LNDC).

Cadiz (NASDAQ:CDZI) and Ocean Bio-Chem (NASDAQ:OBCI) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Profitability

This table compares Cadiz and Ocean Bio-Chem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cadiz-7,255.47%N/A-33.55%
Ocean Bio-Chem17.91%27.70%21.67%

Valuation & Earnings

This table compares Cadiz and Ocean Bio-Chem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadiz$440,000.00890.22$-29,530,000.00N/AN/A
Ocean Bio-Chem$42.26 million2.54$3.50 millionN/AN/A

Ocean Bio-Chem has higher revenue and earnings than Cadiz.

Risk and Volatility

Cadiz has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Ocean Bio-Chem has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Cadiz and Ocean Bio-Chem, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cadiz0000N/A
Ocean Bio-Chem0000N/A

Insider and Institutional Ownership

18.3% of Cadiz shares are owned by institutional investors. Comparatively, 11.1% of Ocean Bio-Chem shares are owned by institutional investors. 2.1% of Cadiz shares are owned by insiders. Comparatively, 62.0% of Ocean Bio-Chem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ocean Bio-Chem beats Cadiz on 7 of the 9 factors compared between the two stocks.

Ocean Bio-Chem (NASDAQ:OBCI) and HF Foods Group (NASDAQ:HFFG) are both small-cap consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Profitability

This table compares Ocean Bio-Chem and HF Foods Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocean Bio-Chem17.91%27.70%21.67%
HF Foods Group-58.85%-0.90%-0.55%

Valuation and Earnings

This table compares Ocean Bio-Chem and HF Foods Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocean Bio-Chem$42.26 million2.54$3.50 millionN/AN/A
HF Foods Group$388.16 million1.01$5.89 millionN/AN/A

HF Foods Group has higher revenue and earnings than Ocean Bio-Chem.

Risk & Volatility

Ocean Bio-Chem has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, HF Foods Group has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Ocean Bio-Chem and HF Foods Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocean Bio-Chem0000N/A
HF Foods Group0000N/A

Insider and Institutional Ownership

11.1% of Ocean Bio-Chem shares are owned by institutional investors. Comparatively, 14.0% of HF Foods Group shares are owned by institutional investors. 62.0% of Ocean Bio-Chem shares are owned by company insiders. Comparatively, 32.5% of HF Foods Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Ocean Bio-Chem beats HF Foods Group on 6 of the 10 factors compared between the two stocks.

Ocean Bio-Chem (NASDAQ:OBCI) and Novus Capital (NASDAQ:NOVS) are both small-cap consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Profitability

This table compares Ocean Bio-Chem and Novus Capital's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocean Bio-Chem17.91%27.70%21.67%
Novus CapitalN/AN/AN/A

Valuation and Earnings

This table compares Ocean Bio-Chem and Novus Capital's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocean Bio-Chem$42.26 million2.54$3.50 millionN/AN/A
Novus CapitalN/AN/AN/AN/AN/A

Ocean Bio-Chem has higher revenue and earnings than Novus Capital.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Ocean Bio-Chem and Novus Capital, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocean Bio-Chem0000N/A
Novus Capital0000N/A

Insider and Institutional Ownership

11.1% of Ocean Bio-Chem shares are owned by institutional investors. Comparatively, 43.8% of Novus Capital shares are owned by institutional investors. 62.0% of Ocean Bio-Chem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Ocean Bio-Chem beats Novus Capital on 5 of the 6 factors compared between the two stocks.

Ocean Bio-Chem (NASDAQ:OBCI) and Calyxt (NASDAQ:CLXT) are both small-cap consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Risk & Volatility

Ocean Bio-Chem has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Calyxt has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500.

Profitability

This table compares Ocean Bio-Chem and Calyxt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocean Bio-Chem17.91%27.70%21.67%
Calyxt-318.57%-89.86%-58.95%

Valuation and Earnings

This table compares Ocean Bio-Chem and Calyxt's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocean Bio-Chem$42.26 million2.54$3.50 millionN/AN/A
Calyxt$7.30 million49.00$-39,610,000.00($1.21)-7.98

Ocean Bio-Chem has higher revenue and earnings than Calyxt.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Ocean Bio-Chem and Calyxt, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocean Bio-Chem0000N/A
Calyxt05302.38

Calyxt has a consensus price target of $9.00, suggesting a potential downside of 6.74%. Given Calyxt's higher probable upside, analysts plainly believe Calyxt is more favorable than Ocean Bio-Chem.

Insider and Institutional Ownership

11.1% of Ocean Bio-Chem shares are owned by institutional investors. Comparatively, 23.8% of Calyxt shares are owned by institutional investors. 62.0% of Ocean Bio-Chem shares are owned by company insiders. Comparatively, 2.3% of Calyxt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Ocean Bio-Chem beats Calyxt on 7 of the 12 factors compared between the two stocks.

Ocean Bio-Chem (NASDAQ:OBCI) and NewAge (NASDAQ:NBEV) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Volatility & Risk

Ocean Bio-Chem has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, NewAge has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Ocean Bio-Chem and NewAge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocean Bio-Chem17.91%27.70%21.67%
NewAge-40.74%-61.13%-23.55%

Valuation & Earnings

This table compares Ocean Bio-Chem and NewAge's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocean Bio-Chem$42.26 million2.54$3.50 millionN/AN/A
NewAge$253.71 million1.37$-89,830,000.00($0.62)-4.66

Ocean Bio-Chem has higher earnings, but lower revenue than NewAge.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Ocean Bio-Chem and NewAge, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocean Bio-Chem0000N/A
NewAge01002.00

NewAge has a consensus price target of $4.50, suggesting a potential upside of 55.71%. Given NewAge's higher probable upside, analysts clearly believe NewAge is more favorable than Ocean Bio-Chem.

Insider & Institutional Ownership

11.1% of Ocean Bio-Chem shares are held by institutional investors. Comparatively, 21.4% of NewAge shares are held by institutional investors. 62.0% of Ocean Bio-Chem shares are held by company insiders. Comparatively, 4.2% of NewAge shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Ocean Bio-Chem beats NewAge on 7 of the 11 factors compared between the two stocks.

Ocean Bio-Chem (NASDAQ:OBCI) and Landec (NASDAQ:LNDC) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Insider & Institutional Ownership

11.1% of Ocean Bio-Chem shares are held by institutional investors. Comparatively, 88.9% of Landec shares are held by institutional investors. 62.0% of Ocean Bio-Chem shares are held by company insiders. Comparatively, 11.9% of Landec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ocean Bio-Chem and Landec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocean Bio-Chem17.91%27.70%21.67%
Landec-8.85%-0.04%-0.02%

Volatility & Risk

Ocean Bio-Chem has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Landec has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Ocean Bio-Chem and Landec, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocean Bio-Chem0000N/A
Landec01302.75

Landec has a consensus price target of $12.75, suggesting a potential upside of 13.54%. Given Landec's higher probable upside, analysts clearly believe Landec is more favorable than Ocean Bio-Chem.

Valuation & Earnings

This table compares Ocean Bio-Chem and Landec's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocean Bio-Chem$42.26 million2.54$3.50 millionN/AN/A
Landec$590.37 million0.56$-38,190,000.00($0.26)-43.19

Ocean Bio-Chem has higher earnings, but lower revenue than Landec.

Summary

Ocean Bio-Chem beats Landec on 7 of the 12 factors compared between the two stocks.


Ocean Bio-Chem Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cadiz logo
CDZI
Cadiz
0.5$11.02+1.4%$391.70 million$440,000.000.00
HFFG
HF Foods Group
0.4$7.52+2.0%$390.39 million$388.16 million-1.14Gap Down
NOVS
Novus Capital
0.2$30.76+1.0%$389.11 millionN/A0.00High Trading Volume
Gap Down
Calyxt logo
CLXT
Calyxt
0.9$9.65+1.1%$357.68 million$7.30 million-7.26Upcoming Earnings
Gap Down
NewAge logo
NBEV
NewAge
1.2$2.89+9.0%$348.33 million$253.71 million-2.39Gap Down
Landec logo
LNDC
Landec
2.0$11.23+0.7%$329.30 million$590.37 million-6.45
FTFT
Future FinTech Group
0.4$5.68+5.6%$326.83 million$950,000.000.00Decrease in Short Interest
Gap Down
Limoneira logo
LMNR
Limoneira
1.8$15.83+3.2%$263.65 million$164.56 million-16.32
LND
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas
0.9$4.16+0.0%$258.35 million$159.94 million8.16Increase in Short Interest
Cresud Sociedad Anónima Comercial, Inmobiliaria, Financiera y Agropecuaria logo
CRESY
Cresud Sociedad Anónima Comercial, Inmobiliaria, Financiera y Agropecuaria
0.7$4.98+1.8%$256.44 million$2.07 billion-1.50
Alico logo
ALCO
Alico
2.3$29.62+0.1%$222.54 million$92.51 million9.37Gap Down
PETZ
TDH
0.4$3.35+5.7%$153.59 million$12.65 million0.00Gap Down
Bridgford Foods logo
BRID
Bridgford Foods
1.0$15.42+0.1%$140.01 million$188.79 million20.84Upcoming Earnings
Gap Down
EDUC
Educational Development
0.9$16.11+3.1%$134.54 million$113.01 million12.30
SEED
Origin Agritech
0.6$23.38+0.1%$132.94 million$13.43 million0.00Decrease in Short Interest
Gap Down
Lee Enterprises logo
LEE
Lee Enterprises
0.6$2.24+3.1%$130.71 million$618 million-44.80
S&W Seed logo
SANW
S&W Seed
1.8$3.60+7.5%$126.28 million$79.58 million-5.54
Blue Apron logo
APRN
Blue Apron
1.0$9.13+3.5%$123.63 million$454.87 million-2.25Decrease in Short Interest
DAVIDsTEA logo
DTEA
DAVIDsTEA
0.4$3.74+1.3%$98.10 million$146.49 million-3.94Increase in Short Interest
NUZE
NuZee
0.7$6.40+3.8%$95.60 million$1.40 million0.00High Trading Volume
Decrease in Short Interest
Gap Down
WTER
The Alkaline Water
1.8$1.22+5.7%$94.74 million$41.14 million-4.36Gap Down
Lifeway Foods logo
LWAY
Lifeway Foods
0.9$5.82+2.1%$90.82 million$93.66 million22.39Gap Down
Yield10 Bioscience logo
YTEN
Yield10 Bioscience
1.6$16.03+9.9%$73.82 million$810,000.00-0.75Decrease in Short Interest
News Coverage
Gap Down
Reed's logo
REED
Reed's
1.2$1.10+4.5%$69.75 million$33.82 million-5.24Gap Down
AXR
AMREP
0.5$7.46+8.3%$54.63 million$18.78 million-27.63Upcoming Earnings
A.H. Belo logo
AHC
A.H. Belo
1.1$2.09+2.4%$44.75 million$183.56 million-7.21Decrease in Short Interest
News Coverage
RIBT
RiceBran Technologies
0.9$1.01+5.0%$42.39 million$23.71 million-2.81Earnings Announcement
Gap Down
WVVI
Willamette Valley Vineyards
1.0$7.85+1.4%$38.94 million$24.75 million18.69Increase in Short Interest
PLIN
China Xiangtai Food
0.6$1.11+0.0%$33.90 million$110.55 million0.00Increase in Short Interest
Gap Down
Coffee logo
JVA
Coffee
0.5$5.01+0.0%$28.60 million$86.47 million-501,000.00Decrease in Short Interest
FAMI
Farmmi
0.6$1.39+7.9%$28.52 million$30.84 million0.00Increase in Short Interest
Gap Down
Eastside Distilling logo
EAST
Eastside Distilling
0.7$1.87+1.6%$18.98 million$17.02 million-1.22Gap Up
CHSCP
CHS
0.5$29.45+0.3%$0.00$28.41 billion0.00
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.